U.S. markets open in 2 hours 49 minutes
  • S&P Futures

    4,408.00
    +59.00 (+1.36%)
     
  • Dow Futures

    34,517.00
    +332.00 (+0.97%)
     
  • Nasdaq Futures

    14,432.25
    +291.50 (+2.06%)
     
  • Russell 2000 Futures

    2,030.40
    +29.10 (+1.45%)
     
  • Crude Oil

    85.95
    +0.35 (+0.41%)
     
  • Gold

    1,844.80
    -7.70 (-0.42%)
     
  • Silver

    23.92
    +0.02 (+0.08%)
     
  • EUR/USD

    1.1283
    -0.0023 (-0.20%)
     
  • 10-Yr Bond

    1.7830
    0.0000 (0.00%)
     
  • Vix

    28.69
    -1.21 (-4.05%)
     
  • GBP/USD

    1.3517
    +0.0011 (+0.08%)
     
  • USD/JPY

    114.1600
    +0.2940 (+0.26%)
     
  • BTC-USD

    37,939.34
    +1,549.91 (+4.26%)
     
  • CMC Crypto 200

    864.77
    +44.18 (+5.38%)
     
  • FTSE 100

    7,485.93
    +114.47 (+1.55%)
     
  • Nikkei 225

    27,011.33
    -120.01 (-0.44%)
     

ESSA Pharma, Caris Life Sciences Ink Liquid Biopsy Profiling Pact

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • EPIX
  • Caris Life Sciences and ESSA Pharma Inc (NASDAQ: EPIX) have announced a Precision Development program to support ESSA's development of EPI-7386 in metastatic castration-resistant prostate cancer (mCRPC) failing current standard-of-care therapies.

  • Under the terms of the agreement, Caris and ESSA will evaluate patient blood samples to assess genetic profiles utilizing Caris' Whole Transcriptome Sequencing and Whole Exome Sequencing platform.

  • ESSA will utilize these liquid biopsies, including longitudinal data from serial samples, to better characterize the tumor biological profiles of patients in the ongoing monotherapy clinical trial of EPI-7386 in mCRPC patients.

  • The information may facilitate more efficient development of EPI-7386 by identifying relevant patient tumor biological subpopulations, the Company said.

  • Price Action: EPIX stock is down 1.13% at $7.86 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.